Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 09, 2026
Trip.com Group (TCOM) Shares Drop -12.4% Over 30 Days on Weak Guidance and China Probe

Trip.com Group (TCOM) Shares Drop -12.4% Over 30 Days on Weak Guidance and China Probe

Key Takeaways

  • TCOM shares fell approximately 12.4% over the past 30 days, closing at $41.38 on July 8, 2026, down from $47.21 on June 8.
  • The sharpest single-day decline occurred on June 25 after the company reported Q1 2026 earnings and issued significantly weaker Q2 revenue guidance of just 3%–8% year-over-year growth.
  • Disclosure of an ongoing anti-monopoly investigation by China's State Administration for Market Regulation (SAMR) added substantial regulatory uncertainty.
  • Multiple Wall Street analysts cut price targets, with Macquarie downgrading the stock to Neutral and Zacks Research issuing a Strong Sell rating.
  • International and inbound travel bookings remained bright spots, surging 65% and 90% year-over-year respectively in Q1 2026.

Trip.com Group (TCOM) Company Overview and Market Position

Trip.com Group Limited is a leading global one-stop travel service provider, offering accommodation reservation, transportation ticketing, packaged tours, and corporate travel management. Founded in 1999 and listed on Nasdaq in 2003, the company operates a portfolio of well-known brands including Ctrip, Qunar, Trip.com, and Skyscanner. Headquartered in Shanghai with a presence across Asia and increasingly in international markets, Trip.com Group is the dominant online travel agency in China and competes with global platforms such as Booking Holdings (BKNG) and regional rivals including Alibaba (BABA)-backed Fliggy. The company generates approximately 79% of its revenue from accommodation reservations and transportation ticketing, supported by a massive liquidity position of $15.1 billion in cash and investments as of March 31, 2026.

Trip.com Group (TCOM) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, TCOM declined from a closing price of $47.21 on June 8, 2026, to $41.38 on July 8, 2026, representing a drop of approximately 12.4%. The most severe intraday sell-off occurred on June 25, when shares plunged as much as 15% and touched a 52-week low of $38.04 following the company's Q1 2026 earnings release and disappointing forward guidance. The stock has since stabilized in the $40–$42 range but remains under pressure.

Looking at the broader quarterly trend, TCOM has been in a sustained downtrend. From early May 2026 levels around $52–$53, the stock has shed roughly 22% of its value. Year-to-date, the decline exceeds 43%, far outpacing the broader Hang Seng Tech Index's decline of approximately 20% over the same period. The stock's 52-week range now stands at $38.04 to $78.99, underscoring the magnitude of the repricing that has occurred in 2026.

What Drove TCOM Stock Price in the Last 30 Days

The primary catalyst for the 30-day decline was Trip.com Group's Q1 2026 earnings report released on June 24–25. While total net revenues grew 17% year-over-year to RMB16.2 billion ($2.4 billion), GAAP net income fell 42% to RMB2.5 billion ($367 million), driven by lower other income and higher tax expenses. More critically, management guided for Q2 2026 net revenue growth of only 3%–8% year-over-year, a dramatic deceleration from Q1's 17% pace. The company cited macro headwinds including elevated energy prices and geopolitical volatility, alongside compliance-related operational adjustments.

Compounding the sell-off, Trip.com Group disclosed that it is cooperating with an anti-monopoly investigation by China's SAMR, which began in January 2026. The investigation examines whether the company abused a dominant market position under the PRC Anti-Monopoly Law. The company warned that findings could result in significant fines, financial penalties, or mandated business practice changes with a material adverse effect on financials. This regulatory overhang triggered a wave of analyst actions: Macquarie downgraded TCOM to Neutral from Outperform and slashed its price target to $44.30 from $70.90, while Citi, Barclays, Benchmark, Mizuho, and Nomura all reduced their targets. Zacks Research subsequently downgraded the stock to Strong Sell.

What Drove TCOM Stock Performance Over the Last Quarter

The quarterly decline reflects a broader reassessment of Trip.com Group's growth narrative. After 13 consecutive quarters of double-digit revenue growth dating back to Q1 2023, the abrupt guidance for single-digit expansion in Q2 2026 signaled that the post-pandemic travel recovery cycle may be maturing faster than anticipated. Rising fuel costs have dampened long-haul travel demand, while domestic regulatory pressure has forced the company to adjust train ticketing value-added services and hotel business practices. The SAMR investigation adds a layer of uncertainty reminiscent of the regulatory crackdowns that previously affected Chinese platform companies such as Alibaba and Meituan. Although Trip.com Group's international business continues to show strong momentum — with international platform bookings up 65% and inbound travel bookings surging 90% in Q1 — the near-term earnings visibility has diminished considerably, prompting institutional investors to reassess position sizing.

Trending AI Robots

In a market environment where stocks like Trip.com Group (TCOM) face heightened volatility and regulatory uncertainty, traders are increasingly turning to data-driven tools to navigate shifting conditions. I also checked this using Tickeron’s Trending AI Robots page, which offers a curated selection of top-performing AI-powered trading bots from a universe of hundreds that trade thousands of tickers. Only the most relevant and consistently performing bots appear in this section, each employing distinct strategies, timeframes, and performance metrics tailored to different market conditions. Whether you are looking for short-term momentum plays or longer-duration trend-following approaches, the Trending AI Robots page provides a streamlined way to explore AI-driven trading solutions designed to adapt to evolving market dynamics.

TCOM Stock Forecast Drivers: What Investors Should Watch Next

Investors should closely monitor the outcome of the SAMR anti-monopoly investigation, as any penalty announcement or mandated business practice changes could materially impact Trip.com Group's monetization model and earnings trajectory. The company's Q2 2026 earnings report, expected in the coming months, will be critical in validating whether the 3%–8% revenue growth guidance was conservative or indicative of a more sustained slowdown. Key metrics to watch include accommodation and transportation booking volumes, international platform growth rates, and margin trends amid rising sales and marketing expenses. Macroeconomic factors — particularly oil prices, Chinese consumer confidence, and geopolitical developments — will continue to influence travel demand. Additionally, any updates on the company's $5 billion share repurchase authorization, which remains largely unexecuted, could signal management's confidence in the stock's valuation. Competitive dynamics with Fliggy, Meituan, and global OTAs will also shape the investment narrative in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TCOM

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


TCOM's RSI Oscillator ascends from oversold territory

The RSI Indicator for TCOM moved out of oversold territory on October 05, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 24 of the 30 cases the stock moved higher. This puts the odds of a move higher at 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for TCOM just turned positive on October 05, 2026. Looking at past instances where TCOM's MACD turned positive, the stock continued to rise in 33 of 50 cases over the following month. The odds of a continued upward trend are 66%.

Following a +3.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where TCOM advanced for three days, in 218 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

TCOM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TCOM as a result. In 60 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.

TCOM moved below its 50-day moving average on September 01, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for TCOM crossed bearishly below the 50-day moving average on September 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCOM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.

The Aroon Indicator for TCOM entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.060) is normal, around the industry mean (24.492). P/E Ratio (7.726) is within average values for comparable stocks, (52.914). Projected Growth (PEG Ratio) (1.911) is also within normal values, averaging (1.617). Dividend Yield (0.005) settles around the average of (0.024) among similar stocks. P/S Ratio (2.767) is also within normal values, averaging (2.686).

The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. TCOM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCOM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Booking Holdings Inc. (NASDAQ:BKNG), Royal Caribbean Group (NYSE:RCL), Expedia Group (NASDAQ:EXPE), Carnival Corporation Ltd. (NYSE:CCL), Trip.com Group Limited (NASDAQ:TCOM).

Industry description

Consumer sundries companies make products that usually do not have another classification, such as lawn and garden products, pest-control products, pet food and pet products like leashes, collars, and harnesses. Central Garden & Pet Company and Dogness (International) Corporation are examples of companies operating in this industry.

Market Cap

The average market capitalization across the Consumer Sundries Industry is 23.73B. The market cap for tickers in the group ranges from 4.32M to 123.13B. BKNG holds the highest valuation in this group at 123.13B. The lowest valued company is SOSAF at 4.32M.

High and low price notable news

The average weekly price growth across all stocks in the Consumer Sundries Industry was 2%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 7%. LIND experienced the highest price growth at 20%, while YTRA experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the Consumer Sundries Industry was -17%. For the same stocks of the Industry, the average monthly volume growth was 56% and the average quarterly volume growth was -44%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 66
Price Growth Rating: 57
SMR Rating: 55
Profit Risk Rating: 80
Seasonality Score: 15 (-100 ... +100)
View a ticker or compare two or three
TCOM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in the provision of travel-related services

Industry ConsumerSundries

Industry
N/A
Address
30 Raffles Place
Phone
+65 31389736
Employees
43574
Web
https://group.trip.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.